The Bush Legacy: Generics, Not Price Controls
This article was originally published in The Pink Sheet Daily
Executive Summary
President reflects on Medicare Part D and the potential for price controls during farewell appearance at AEI event.
You may also be interested in...
How Much Reform And How Fast? Key Questions For Presidential Address
Balance between push to expand coverage and restrain spending will be key for biopharma industry in analyzing Obama address Tuesday night. Here is a list of items to listen for.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.